Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus hippocampal-sparing IMRT whole-brain radiotherapy for NSCLC with brain metastases
ChiCTR-IIR-17012487Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Median overall survival and Overall survival rate at 1 year. Started Sep 2016; status: recruiting.
02
Drugs
temozolomide
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR-IIR-17012487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012487.